Supplementary Materials for





Supplementary Figure 1. **a**, **b** IL-10 level in BALF supernatant (**a**) and serum (**b**) of ALI mice at different time points upon LPS treatment. n = 6 per group. All samples were biologically independent and three or more independent experiments with similar results were performed. Data are presented as mean \pm SEM and analyzed with a 95% confidence interval. Statistical analysis was performed using one-way ANOVA followed by Bonferroni's post hoc test. Source data are provided as a Source Data file.



Supplementary Figure 2. Representative histological images of H&E-stained lung sections from WT and $II-10^{-/-}$ mice at 12 h after LPS inhalation. Scale bars in the upper panel, 1 mm; scale bars in the below panel, 50 μ m. Three independent experiments with similar results were performed.



Supplementary Figure 3. The effects of $Il-10^{-/-}$ comparing to WT on survival of the severe ALI mice. n = 14, 14, 15, 15, respectively in each group. *p = 0.0261 versus WT-LPS group. All samples were biologically independent and three or more independent experiments with similar results were performed. Data are analyzed with a 95% confidence interval. Statistical analysis was performed using Log-rank test. Source data are provided as a Source Data file.



Supplementary Figure 4. a-f Mice were co-injected nasally with PBS or recombinant IL-10 (rIL-10; 45 μ g/kg) together with LPS (10 mg/kg). Animals were euthanized 24 h after LPS stimulation for the analysis of total cell counts (**a**, n = 6 per group), H&E staining of cells (**b**, scale bars, 50 μ m), neutrophil numbers (**c**, n = 6 per group), macrophage counts (**d**, n = 6 per group), lymphocyte numbers (**e**, n = 6 per group) and total protein in BALF (**f**, n = 6, 6, 7 in each group). **g-h** Production of IL-6 in BALF (**g**) and serum (**h**) is shown, n = 5 per group. ns, not significant. All samples were biologically independent and three or more independent experiments with similar results were performed. Data are presented as mean \pm SEM and analyzed with a 95% confidence interval. Statistical analysis was performed using one-way ANOVA followed by Bonferroni's post hoc test. Source data are provided as a Source Data file.



Supplementary Figure 5. a Representative histological images of H&E-stained lung sections at 24 h after LPS inhalation in the presence or absence of rIL-10 administration. Scale bars in the upper panel, 1 mm; scale bars in the below panel, 50 μ m. **b-d** Immunohistochemical staining with Ly6G (b), MPO (c) and NE (d) in mouse lung sections. Scale bars, 50 μ m. Three independent experiments with similar results were performed.



Supplementary Figure 6. **a-j** Violin plots of gene expression in single cells of each population from lungs of WT control, WT LPS-treated and *Il-10^{-/-}* LPS-treated mice for described markers in the literature for epithelial cells (**a**), endothelial cells (**b**), fibroblasts (**c**), neutrophils (**d**), monocyte-macrophages (Mono-Macro) (**e**, **f**), lymphocyte T-cells (**g**), lymphocyte B-cells (**h**), dendritic cells (DC) (**i**) and natural killer (NK) cells (**j**). Boxes within violin plot show the median \pm 1 quartile, with the whiskers extending from the hinge to the smallest or largest value within 1.5 × interquartile range from the box boundaries. *n* = 469, 168, 683, 7071, 2618, 566, 140, 55, 100, respectively.



Supplementary Figure 7. Proportions of neutrophil populations in lung tissues of $Il-10^{-/-}$ (left) and WT (right) mouse at 24 h after LPS stimulation.



Supplementary Figure 8. **a**, **b** Heatmaps of the top differentially expressed genes in each neutrophil population compared to the others. **c-e** Immunohistochemical staining was performed for Fth1 to determine the distribution of the Fth1^{hi} Neu subset in ALI lung tissues. Scale bars, 100 μ m (**c**); scale bars, 20 μ m (**d**, **e**). Blue arrowheads indicate neutrophils in airways (**d**) and pulmonary vessels (**e**). Three independent experiments with similar results were performed.





Supplementary Figure 9. a, b GO enrichment and KEGG pathway analyses of individual neutrophil subsets in ALI lungs from $II-10^{-/-}$ (a) and WT (b) mice. Red boxes indicate the

.....

differential functions between Fth1^{hi} (N1-N5) and Prok2^{hi} (N6 and N7) neutrophils. The statistical analysis was performed by Fisher's test.



Supplementary Figure 10. a, b Transfection of human promyelocytic leukemia (HL-60) cells with Fth1/Prok2 shRNA downregulated the mRNA (a) and protein (b) expression at 12 h compared with control shRNA treatment. n = 3 per group. c-f Fth1-depleted neutrophils exhibited function defects in anti-oxidation (c), anti-apoptosis (e) and chemotaxis (f), while Prok2-deficient neutrophils defected in ROS production (c), phagocytosis (d) and chemotaxis (f) of HL-60 cell-derived neutrophils compared with NEGi. n = 4 per group. (g) Immunoblotting verifying the effects of Fth1/Prok2 on anti-oxidant HO-1 and pro-apoptotic Bax expression, as well as NLRP3 and cleaved Caspase-1 level for inflammasome activation.

ns, not significant. All samples were biologically independent and three or more independent experiments with similar results were performed. Data are presented as mean \pm SEM and analyzed with a 95% confidence interval. Statistical analysis was performed using two-tailed unpaired Student t test. Source data are provided as a Source Data file. Uncropped scans of western blot with molecular weight markers were provided in Supplementary Figure 16.



Figure 11. Representative images **Supplementary** a of anti-Fth1/anti-Ly6G immunofluorescence-stained lung sections of mice with or without rIL-10 treatment 24 h after LPS challenge. The nuclei were stained with DAPI and are displayed in blue. Scale bars, 50 µm. b Representative images of anti-Fth1 immunofluorescence-stained airway neutrophils of mice with or without rIL-10 administration 24 h after LPS stimulation. The nuclei were stained with DAPI, displayed in blue. Scale bars, 20 µm. Three independent experiments with similar results were performed. c Gating strategy and representative scatter plots of BALF cells collected from WT and Il-10^{-/-} mice at 24 h after LPS challenge. Cellular apoptosis was evaluated by flow cytometry.



Supplementary Figure 12. **a** BALF was collected from WT and *ll-10^{-/-}* mice for identifying total counts of inflammatory cells on day 4 and day 7 after LPS challenge, n = 4 in each group. **b** TUNEL staining of apoptotic cells (green) and DAPI staining of nuclei (blue) in lung sections at 4 d and 7 d post-exposure. ns, not significant. All samples were biologically independent and three or more independent experiments with similar results were performed. Data are presented as mean \pm SEM and analyzed with a 95% confidence interval. Statistical analysis was performed using two-tailed unpaired Student t test. Source data are provided as a Source Data file.



Supplementary Figure 13. a-h The volcano plots (upper) and heatmaps (below) showing the

differentially expressed genes in BALF and blood neutrophils from distinct management groups at different time points. n = 4 samples per group. VS, versus. p values were calculated with a likelihood ratio test between groups.



Supplementary Figure 14. **a-h** GO terms and KEGG pathway analyses of BALF and blood neutrophils in different treatment groups at different time points. n = 4 samples per group. VS, versus. The statistical analysis was performed by Fisher's test.



Supplementary Figure 15. **a-c** Gating strategy for the detection of ROS (**a**), phagocytosis (**b**) and apoptosis (**c**) of HL-60 cell-derived neutrophils.



Supplementary Figure 16. **a-c** Uncropped scans of western blot with molecular weight markers, which are related with Supplementary Figure 10.

	Age, Yrs,	Sex	Smoking	Pack-years,	Cancer	Current	Sample		Hypertension	Diabetes	Cardiac	Autoimmune	Others		Survival
	(M, IQR)			Yrs	history	disease					disease	diseases	<u> </u>	-	
All% or median	67(49-88)	62.50% Male	8.33%	-	16.67%	-			41.67%	12.5%	16.67%	4.17%	50.00%		75.00%
Case 1	49	F ª	×	-	×	SP ° Pneumonia			~	×	4	×	×		~
Case 2	54	M ^b	4	30	×				×	~	×	×	×		~
Case 3	66	F	×	-	4				×	×	×	×	×		~
Case 4	85	М	×	-	×				×	×	×	×	4		~
Case 5	64	F	×	-	×	KP ^d Pneumonia			×	~	×	×	×		~
Case 6	64	F	×	-	4		Pneumonia HI ° Lung Cancer Pulmonary	Underlying diseases	~	×	×	×	×		~
Case 7	71	М	×	-	4				×	×	×	×	×		~
Case 8	73	М	×	-	×	Ηι∘			~	×	×	×	×		~
Case 9	70	М	×	-	×				×	×	×	×	4		~
Case 10	66	М	×	-	×				~	×	4	×	×	Q	~
Case 11	64	F	×	-	7	Lung Cancer			×	×	×	×	×	lcome	~
Case 12	54	М	×	-	×				×	×	×	×	4		~
Case 13	87	F	×	-	×				×	×	×	×	×		~
Case 14	61	F	×	-	×	Pulmonary			×	×	×	×	4		~
Case 15	72	М	×	-	×	Fibrosis AECOPD ^r		~	×	×	×	×		~	
Case 16	67	F	×	-	×				×	×	×	×	4		4
Case 17	54	М	4	30	×				×	×	×	×	4		~
Case 18	72	М	×	-	×	ARDS 8			~	×	4	×	×		×
Case 19	71	М	×	-	×				×	~	×	4	4		×
Case 20	70	F	×	-	×				~	×	×	×	~		×
Case 21	65	М	×	-	×				×	×	×	×	4		×
Case 22	66	М	×	-	×				~	×	×	×	4		~
Case 23	88	М	×	-	×				~	×	×	×	4		×
Case 24	84	М	×	-	×				~	×	4	×	~		×

Supplementary Table 1: Demographic and clinical characteristics of 24 patients.

^a F: Female. ^b M: Male. ^c SP: *Streptococcus pneumoniae*. ^d KP: *Klebsiella pneumoniae*. ^e HI: *Haemophilus influenzae*. ^f AECOPD: Acute exacerbation of chronic obstructive pulmonary disease. ^g ARDS: Acute respiratory distress syndrome.